<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE332nnn/GSE332993/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE332993</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Cobalt-mediated suppression of IFNγ-JAK-STAT1 signaling reprograms IDO1-driven immunosuppression for metalloimmunotherapy</name><description>Metal ions are increasingly recognized as dynamic regulators of immune function, yet their systematic exploitation for cancer immunotherapy remains underexplored. Indoleamine 2,3-dioxygenase 1 (IDO1), an interferon-γ (IFNγ)-inducible immune checkpoint frequently upregulated in solid malignancies, catalyzes tryptophan degradation to kynurenine and establishes a metabolically immunosuppressive tumor microenvironment. Although IDO1 represents an attractive therapeutic target, strategies to modulate its activity with precision are limited. Here we identify cobalt ions (Co2+) as potent suppressors of IFNγ-induced IDO1 expression through a systematic screen of biologically relevant metal ions. Across multiple cancer cell lines, Co2+ markedly attenuated IDO1 expression and reduced kynurenine production. Mechanistically, Co2+ disrupted IFNγ-JAK-STAT1 signaling by engaging main receptor of IFNγ, IFNGR1, promoting its destabilization and degradation, thereby constraining tumor cell-intrinsic IDO1 induction, re-established kynurenine/tryptophan metabolic homeostasis and alleviating CD8+T cell exhaustion. These effects reprogrammed the immunosuppressive niche towards enhanced cytotoxic T cell function. To mitigate the off-target toxicity and immune cell damaging associated with free Co2+, we engineered ConaHA, a hyaluronic acid-based nanoparticle platform that enables sustained cobalt release and tumor-directed delivery. ConaHA potentiated cobalt-mediated immune checkpoint blockade while improving therapeutic tolerability in vivo, which dramatically improved the antitumor efficacy in subcutaneous Panc02, MC38 and B16F10 tumor models. Collectively, these findings uncover a previously unappreciated immunoregulatory function of Co2+ and establish a conceptual framework for metalloimmunotherapy through targeted modulation of metal-immune signaling axes.</description><dates><publication>2026/09/23</publication></dates><accession>GSE332993</accession><cross_references><GSM>GSM9756813</GSM><GSM>GSM9756814</GSM><GSM>GSM9756817</GSM><GSM>GSM9756818</GSM><GSM>GSM9756815</GSM><GSM>GSM9756816</GSM><GSM>GSM9756819</GSM><GSM>GSM9756820</GSM><GSM>GSM9756821</GSM><GPL>24247</GPL><GSE>332993</GSE><taxon>Mus musculus</taxon><PMID>[42758828]</PMID></cross_references></HashMap>